Medical Device Morning Brief - August 21: Policy Updates, Product Approvals, and Industry Dynamics

Tianjin CityThe Medical Insurance Bureau issues the "Detailed Rules for the Implementation of Designated Management of Long-term Care Insurance Nursing Service Institutions in Tianjin City"

Tianjin Municipal Medical Insurance Bureau Releases "Detailed Rules for the Implementation of定点Management of Long-term Care Insurance Nursing Service Institutions" (Document No. [2023]津Medicare Regulations)[2025] No. 2), effective from August 18, 2025, to August 17, 2030, while abolishing the 2023 version of the management measures. The detailed rules specify that long-term care service institutions must be equipped with professional personnel, establish sound accounting systems, standardize services through contractual management and networked settlement, strengthen fund supervision, and promote service standardization and informatization.

New Regulations for Medical Device Conversion in Shanghai

Shanghai recently announced on its official websiteInterpretation of the Regulations on the Transfer of Medical Device Products with Registration Certificates to Production in ShanghaiMentioned in"The Regulations on the Transfer of Medical Device Products with Registration Certificates to Production in Shanghai" have beenIssued on August 14, 2025, and implemented from October 1. Applicable to the transition production of Class II medical devices, requiring the original registrant and the transition applicant to be under the same actual controller. It details registration materials, system verification requirements, and establishes consulting services, etc.

Affiliated Tumor Hospital of Xinjiang Medical University - Ultra High-EndCT Tender Announcement

Tender Announcement for the Procurement of Premium High-End Equipment by the Affiliated Tumor Hospital of Xinjiang Medical UniversityCT equipment, with a budget amount of 25 million yuan, requires delivery and completion of installation and debugging within 40 days.

Approved for registration by the National Medical Products Administration295 Medical Device Products

On August 20, the National Medical Products Administration announced that a total of 295 medical device products were approved for registration in July 2025, including 240 Class III devices produced in China, 21 imported Class III devices, 29 imported Class II devices, and 5 from Hong Kong, Macao, and Taiwan.

MedtronicForce2FY6 Q1Revenue61.7 Billion: Cardiovascular Business Surpassed by Boston Scientific

In Q1 of FY2026, Medtronic reported revenue of $8.6 billion (up 8.4% year-over-year), with a slight decline in net profit. All four business units grew, led by Diabetes (+11.5%), while Cardiovascular (+9.3%) was surpassed by Boston Scientific (over $3.3 billion). Highlights included strong PFA performance and renal denervation potentially entering national insurance; plans involve spinning off the Diabetes business into MiniMed (IPO within 15 months), and adding board members to drive growth.

MedtronicMedtronic Heart Valve Patent Infringement Ruling Overturned

Medtronic Found Liable for Infringing Colibri Heart Valve Patent in First Instance$106.5 million, but the appellate court overturned the original ruling, leading to a major reversal in the case.

Cryomod: Micro-guidewire Approved for Market to Enhance Interventional Procedures"Precision Navigation"

Cryomodulation Guidewire by Sinocare Approved for Marketing, with Four Core Advantages to Meet Clinical Needs for Precise, Safe, and Efficient Interventional Devices, Marking a Significant Breakthrough for the Company in the Vascular Intervention Field.

WondfoBiological2025Only 9 institutions disclosed their holdings in the second quarter.

Wondfo BiotechAs of Q2 2025, there are 9 institutional holders with a total shareholding of 86,393,900 shares, accounting for 17.95% of the total shares, marking an increase of 1.10% in institutional ownership. Changes have been observed in the holdings of public funds, social security funds, and foreign institutions.

ChinaChina's First Batch, WestNan FirstProton Therapy Center Officially Begins Operation Today

The Proton Therapy Center of Sichuan Cancer Hospital Begins Operation, Marking the Entry of Western China into a New Era of Cancer Prevention and Treatment"Proton Era": The technology precisely targets, expands the treatment scope, and the first patient has been successfully treated.

First Made in ChinaRFQNCT System Completes First Clinical Treatment

First domestically producedRFQ-BNCT System Successfully Completes First Clinical Treatment of Recurrent Nasopharyngeal Cancer, Marking China's Achievement of Technological Independence in Precision Radiotherapy and Opening New Pathways for Cancer Treatment. Significant Symptom Relief Observed in Patient Within Three Days, Validating the Clinical Feasibility of China-Produced Equipment.

AnotherMedical Device Company Applies for BreakthroughProduction

On August 8, Beijing Ruizheng Shanda Bio-Technology was applied for bankruptcy liquidation due to its inability to repay due debts and insolvency. The company mainly engages in the R&D and production of clinical biochemical and immunoassay products, with about 50 registered products. As of October 31, 2023, the company's total assets amounted to more than 430,000 yuan, with total liabilities nearing 9 million yuan.

Leadership Changes in Major Hospitals Across Multiple Regions: New Appointments for Hospital Directors and Party Secretaries

Recently, the leadership of several hospitals, including China-Japan Friendship Hospital, Zhejiang Provincial People's Hospital, Chengdu Second People's Hospital, Chengdu Third People's Hospital, Yinchuan First People's Hospital, Yinchuan Second People's Hospital, Yinchuan Third People's Hospital, and Foshan First People's Hospital, have been changed, involving positions such as president and party secretary.

That concludes the entirety of today's news broadcast.

Want to be the first to grasp the latest news and in-depth insights of the medical device industry? Add the official customer service WeChat of "Medical Device Innovation Network," join the exclusive reader group, and get real-time updates, exchange with peers, and spark thoughts.

In the industry upsurge, precise decision-making requires not only practical experience but also data support.Original PriceThe CEO Training Camp, originally priced at 6800 yuan, is now only 389 yuan, and comes with a gift worth 389 yuan: "China Medical Device Industry Data Report (Equipment Chapter)+Consumables Chapter)》！

The Special Training Camp gathers industry leaders to teach you the entire practical process of product development, production, registration, certification, and sales. With real-world experience, they help you avoid pitfalls and take the right path. The Blue Book, produced by the Social Sciences Academic Press, covers industry trends, market size, and data on niche sectors, helping you pinpoint your direction and make scientific plans.(The content is so substantial that the editor has been reading it for a month and is still slowly digesting it.)。

Whether it's for corporate operations, investment decisions, or research references, this combination provides you with practical methods and data support.First come, first served. Hurry up!Contact a dedicated consultant for more informationOh。